Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

RxSight, Inc. - Common Stock (NQ:RXST)

8.430 +0.210 (+2.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about RxSight, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Stifel Maintains Buy Rating for RxSight: Here's What You Need To Know
 
Via Benzinga
Insiders are selling these hot stocks on track for higher prices
Insiders are selling these hot stocks and may cap gains in the near term, but long-term gains are in the outlook. Analysts support them and raise their targets. 
Via MarketBeat
The Analyst Landscape: 8 Takes On RxSight
 
Via Benzinga
Jim Cramer: This Healthcare Stock Is 'Too Risky,' But Shares Jumped 64% Over Past Month
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is "too risky." 
Via Benzinga
3 Stocks to Buy BEFORE They Become Household Names
The best way to find 100 baggers is to invest in undiscovered stock gems that have yet to become household names. 
Via InvestorPlace
Breaking Down RxSight: 5 Analysts Share Their Views
 
Via Benzinga
Analyst Expectations for RxSight's Future
 
Via Benzinga
RxSight: Q3 Earnings Insights
 
Via Benzinga
Where RxSight Stands With Analysts
 
Via Benzinga
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on... 
Via Benzinga
RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Financial and Operational Results and 2024 Guidance
From RxSight, Inc.
Via GlobeNewswire
RxSight's Earnings: A Preview
 
Via Benzinga
The Latest Analyst Ratings for RxSight
 
Via Benzinga
Analyst Expectations for RxSight's Future
 
Via Benzinga
Looking Into RxSight's Return On Capital Employed
 
Via Benzinga
RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference
From RxSight, Inc.
Via GlobeNewswire
RxSight, Inc. Reports Third Quarter 2023 Financial Results
From RxSight, Inc.
Via GlobeNewswire
RxSight, Inc. Educational and Product Announcements for AAO 2023
From RxSight, Inc.
Via GlobeNewswire
RxSight, Inc. to Report Third Quarter Financial Results on November 9, 2023
From RxSight, Inc.
Via GlobeNewswire
RxSight, Inc. to Present at the Wells Fargo Healthcare Conference
From RxSight, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
RxSight, Inc. Reports Second Quarter 2023 Financial Results
From RxSight, Inc.
Via GlobeNewswire
RxSight, Inc. to Report Second Quarter Financial Results on August 7, 2023
From RxSight, Inc.
Via GlobeNewswire
RxSight Is A Potential Acquisition Target: Analyst Highlights How LAL Revenue Mix Could Drive Share Price To $45+
Needham analyst David Saxon reiterated a Buy rating on RxSight, Inc. (NASDAQ: RXST),  
Via Benzinga
RxSight, Inc. Reports First Quarter 2023 Financial Results
From RxSight, Inc.
Via GlobeNewswire
RxSight, Inc. to Present at the Bank of America Healthcare Conference
From RxSight, Inc.
Via GlobeNewswire
RxSight, Inc. to Report First Quarter Financial Results on May 9, 2023
From RxSight, Inc.
Via GlobeNewswire
Multiple Surgeon Presentations to Highlight RxSight® Light Adjustable Lens System at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting
From RxSight, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023
 
Via Benzinga
RxSight, Inc. to Present at the Needham Healthcare Conference
From RxSight, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.